Solicitudes de Patente publicadas en los últimos 30 días / Patent Applications last 30 days publications
Nº publicación: HK1211220A1 20/05/2016
UNIVERSIT DE DROIT ET DE SANT DE LILLE II [FR]
UNIVERSIT DE TOURS FRANCOIS RABELAIS [FR]
CT HOSPITALIER RGIONAL UNIVERSITAIRE DE LILLE [FR]
The present invention relates to a pharmaceutical composition for its use in the prophylactic treatment in a patient against an intracellular pathogen, said composition comprising a solid nanoparticle comprising a cationic-polysaccharide solid core, said core being porous and loaded with at least an anionic phospholipid and at least an antigen coming obtained from said pathogen.
Nº publicación: US2016137722A1 19/05/2016
US OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN [US]
Disclosed herein are isolated humanized monoclonal antibodies that specifically bind Japanese encephalitis virus (JEV) with a binding affinity of about 1.0 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. Methods of treating, preventing, and/or ameliorating JEV infection in a subject with JEV also are disclosed. Additionally, the antibodies can be used to detect JEV in a sample, and methods of diagnosing JEV infection, or confirming a diagnosis of JEV infection in a subject, are disclosed herein that utilize these antibodies.
Nº publicación: WO2016074334A1 19/05/2016
BEIJING FUIICAN BIO TECHNOLOGY CO LTD [CN]
Disclosed is an application of a micro-nano material in the preparation of targeted therapeutic drugs for tumors. The micro-nano material has the following properties: (1) the material has water dispersibility and solubility so that it can be injected into a living body through veins and transported to tumor vessels and metabolized by the body; (2) the material has a particle size ranging from 10 nm to 500 nm and can be closely retained in pores on the inner walls of the tumor vessels by means of an EPR effect and high pressure in the tumor vessels; (3) during close contact with endothelial cells of the tumor vessels, the material produces a specific physical destroying effect on the endothelial cells of the surrounding tumor vessels under the driving of electromagnetic waves and finally causes tumor necrosis; (4) the material has electronegativity on the surface so that it does not produce non-specific adsorption on inner walls of blood vessels of normal cells and normal tissues and can destroy tumor vessels with high selectivity; and (5) the micro-nano material produces mechanical movement, deformation and volume expansion under the driving of the electromagnetic waves.
Nº publicación: WO2016075977A1 19/05/2016
3 D MATRIX LTD [JP]
UNIV TOKYO SCIENCE FOUNDATION [JP]
The present invention provides a nanogel containing a self-assembling peptide, chitosan, and polyethylene glycol.
Nº publicación: US2016136607A1 19/05/2016
XEROX CORP [US]
The process for manufacturing porous nanoparticles disclosed herein includes feeding a dry-blended mixture of at least one resin and a neutralizing agent into a feed section of a screw extruder, injecting a surfactant solution downstream of the hopper, and adding an aqueous composition both directly after the surfactant solution as well as further downstream. Porous nanoparticles having a particle size of from about 50 nm to about 2 [mu]m and a pore diameter of from about 20 nm to about 400 nm may be continuously recovered from the extruder following this process.
Nº publicación: US2016136308A1 19/05/2016
FLYNN EDWARD R [US]
Embodiments of the present invention provide methods of detecting disease, methods of treating disease using targeted hyperthermia, methods of treating disease using targeted chemical agents, methods of treating disease comprising accurate measurements of the efficacy of treatments. The effect of nanoparticles on magnetic fields can be used to determine the location of a disease, and a measure of the number of cells characteristic of the disease. This location and measure can be used to guide therapy, and provide information regarding the most effective therapy to be applied. The same nanoparticles can be used to facilitate hyperthermia treatments, and to allow targeted application of chemical therapeutic agents.
Nº publicación: US2016136303A1 19/05/2016
The present invention relates to compositions and methods for use in medical diagnosis and patient's monitoring. It more particularly relates to a biocompatible gel comprising nanoparticles and/or nanoparticles aggregates, wherein i) the nanoparticle and/or nanoparticles aggregate comprise an inorganic material comprising at least one metal element having an atomic number Z of at least 25, each of said nanoparticle and of said nanoparticles aggregate being covered with a biocompatible coating; ii) the nanoparticles and/or nanoparticles aggregates concentration is of about or less than 0.5% (w/w); and iii) the apparent viscosity at 2s - of the gel comprising nanoparticles and/or nanoparticles aggregates, is between about 0.1 Pa.s and about 1000 Pa.s when measured between 20 DEG C and 37 DEG C. 1 The composition of the invention typically allows the delineation and visualization of at least 40% of the target biological tissue when said tissue is observed using an X-ray imaging equipment.
Nº publicación: US2016136289A1 19/05/2016
US HEALTH [US]
BAYLOR COLEGE OF MEDICINE [US]
USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES [US]
BAYLOR COLLEGE MEDICINE [US]
Embodiments of photoactivatable, lipid-based nanoparticles are disclosed, as well as methods of making and using the nanoparticles. Pharmaceutical compositions including the nanoparticles also are disclosed. The lipid-based nanoparticles include a vesicle wall surrounding a cavity, wherein the vesicle wall includes (i) a lipid bilayer comprising 1,2-bis(tricosa- 10,12- diynoyl)-sn-glycero-3-phosphocholine (DC8,9PC), dipalmitoylphosphatidylcholine (DPPC), and (ii) 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a (HPPH) within the lipid bilayer. The nanoparticles may further include an agent within the cavity.
Nº publicación: US2016137687A1 19/05/2016
UNIV KOREA RES & BUS FOUND [KR]
The present invention relates to a method for preparing a metal nanostructure using a DNA and, more specifically, to a method for preparing a metal nanostructure, which easily controls the orientation, form and size compared to a conventional bottom-up method due to using a DNA having a self-assembling property as a frame. The metal nanostructure prepared by the method exhibits an excellent localized surface plasmon resonance phenomenon, and thus can be used as a fluorescent material in drug delivery, biomedical imaging, supersensitive biosensors, etc.
Nº publicación: US2016136232A1 19/05/2016
UNIV BROWN [US]
A tunable antimicrobial-loaded hydrogel formulation has a mechanical strength can be altered by changing the salt composition. The hydrogel formulation is preferably a Gellan film. The ion concentration in the gel material may be altered to obtain the desired gel strength. The hydrogel formulation is layered directly upon a skin area such as burnt skin. The hydrogel formulation includes a dosage of free antibiotic, such as the antibiotic is preferably vancomycin, for rapid release. The hydrogel formulation also includes microparticles and/or nanoparticles such as activated carbon powder that has adsorbed additional antibiotic. The particles are used to aid in attaining a timely or sustained release of the antibiotic drug.
Nº publicación: US2016136106A1 19/05/2016
UNIV CALIFORNIA [US]
Provided are methods, combinations and pharmaceutical compositions for treating or preventing an infection in a subject using a nanoparticle comprising a) an inner core comprising a non-cellular material, and b) an outer surface comprising a cellular membrane configured for adhesion of a pathogen that causes said infection. Exemplary infection includes infection caused by a virus, bacterium, fungus, or protozoan.
Nº publicación: US2016136105A1 19/05/2016
UNIV NEBRASKA [US]
In accordance with the instant invention, nanopartides/nanoformulations comprising at least one therapeutic agent and at least one surfactant linked to gp120 are provided. In a particular embodiment, the surfactant is an amphiphilic block copolymer, polysorbate, phospholipid, derivative thereof, or combination thereof. In a particular embodiment, the surfactant is an amphiphilic block copolymer. In a particular embodiment, the nanopartides/nanofonnulations further comprise other surfactants linked to at least one other targeting ligand. An individual nanopartide may comprise targeted and non-targeted surfactants. In a particular embodiment, the therapeutic agent is an antiviral, antiretroviral, or anti-HIV compound. In a particular embodiment, the surfactant is PLGA-PEG. Pharmaceutical compositions comprising at least nanoparticle of the instant invention and at least one pharmaceutically acceptable carrier are also provided.
Nº publicación: US2016136092A1 19/05/2016
THERMOSOME GMBH [DE]
The invention relates to stereospecific lipids for the locoregional therapy with long-term circulating stimuli-sensitive nanocarrier systems. A preferred embodiment thereof is a thermosensitive liposome for treating tumors, especially urinary bladder tumors and other localized tumors.
Nº publicación: AU2014345334A1 19/05/2016
MEDICAL RES COUNCIL
Amorphous magnesium-substituted calcium, phosphate compositions and their medical uses are described, in particular for use in delivering cargo materials, such as cargo molecules or cargo nanoparticles contained in pores of the amorphous magnesium- substituted calcium phosphate to cells of the immune system, fo example as therapeutic approaches for the treatment of inflammatory bowel diseases, and in particular Crohn's disease, autoimmune diseases, allergy and for therapeutic vaccination.
Nº publicación: WO2016077739A1 19/05/2016
UNIV MISSOURI [US]
A nanoconjugate that includes multiple antibody agents bonded to a single nanoparticles via a linker to form a conjugate having either electrostatic or covalent bonding or that retains original properties of the multiple antibody types prior to formation of the conjugate. Preferred methods provide for multiple antibody types attached to a single nanoparticle via electrostatic attachment, covalent or mixed covalent and electrostatic attachment.
Nº publicación: WO2016077733A1 19/05/2016
UNIV MISSOURI [US]
A preferred embodiment is a method of formation of nanoparticle conjugates for cancer diagnostics, imaging and therapy, wherein the method allows determination a priori the efficacy of the nanoparticle conjugate for treatment of disease. A preferred stable pharmaceutical formulation includes a single antibody agent retaining its functionality in accordance with a predetermination of an a priori efficacy and electrostatically or covalently linked to a nanoparticle in a predetermined ratio in accordance with the a priori efficacy. Preferred embodiments also provide a method for forming single human antibody nanoparticle conjugates. The methods retain properties of the human antibody with a fabrication process that also allows control of the bonding mode of the antibody to the surface of AuNP, such that the bonding mode can be predetermined to be either electrostatic or covalent.
Nº publicación: WO2016076227A1 19/05/2016
II MASAAKI [JP]
OSAKA MEDICAL COLLEGE [JP]
TABATA YASUHIKO [JP]
Provided is a preparation containing statin-encapsulated nanoparticles wherein statin is encapsulated within nanoparticles comprising a bioabsorbable polymer, said nanoparticles having a number-average particle diameter of less than 1000 nm and being to be used for enhancing the function of stem cells. Also provided is a stem cell with enhanced function, said stem cell containing the statin-encapsulated nanoparticles incorporated thereinto.
Nº publicación: JP2016513712A 16/05/2016
The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment ("cholestosome") consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.
Nº publicación: JP2016513657A 16/05/2016
The present invention provides methods and compositions for treating bladder cancer, including metastatic bladder cancer and non-muscle-invasive bladder cancer, by administering a composition comprising nanoparticles that comprise mTOR inhibitor and optionally an albumin.
Nº publicación: HK1108840A1 13/05/2016
VITAL HEALTH SCIENCES PTY LTD [AU]
The invention relates to a carrier for administering biologically active compounds comprising one or more C1-C4 alcohols, polyols and polymers thereof, water and one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof. The carrier may be used in administering biologically active compounds, in particular pharmaceuticals including cosmetic agents.
Nº publicación: WO2016072730A1 12/05/2016
SEOUL NAT UNIVERSITY R&DB FOUNDATION [KR]
The present invention relates to a method for manufacturing metal nanostructures which are anisotropically branched and grown on a surface of a substrate having a first metal surface and, specifically, to a method for manufacturing branched nanostructures, the method comprising: a first step of forming a polydopamine coating layer on the substrate through a linkage of the first metal surface and a catechol group of polydopamine; and a second step of anisotropically branching and growing second metal nanostructures on the first metal substrate surface by oxidizing the catechol group of the polydopamine into quinone through a catalytic action of the metal surface to reduce a second metal precursor while inducing oxidative nanopeeling due to the oxidative disruption of the polydopamine coating layer, and to a use of plasmon particles comprising the thus manufactured metal nanostructures, as a photo-sensitizer for photodynamic and/or photothermal therapy.
Nº publicación: JP2016513075A 12/05/2016
The present invention provides methods and compositions for treating cancer by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a nucleoside analog (e.g., gemcitabine) based upon levels of a nucleoside transporter (e.g., hENT1).
Nº publicación: JP2016513090A 12/05/2016
The present invention relates to the composition of a nanoparticle based on a magnesium salt, and methods of drug delivery using the nanoparticle. A preferred embodiment uses magnesium phosphate, with or without a shell to deliver aiRNA and/or siRNA. The nanoparticles of the present invention are also effective when administered orally.
Nº publicación: JP2016513097A 12/05/2016
Provided herein are methods for the treatment of melanoma comprising administration of a composition comprising nanoparticles comprising taxane and a carrier protein.
Nº publicación: AU2014342097A1 12/05/2016
KALA PHARMACEUTICALS INC
Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.